126 related articles for article (PubMed ID: 1389483)
1. Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin.
Herait P; Poutignat N; Marty M; Bugat R
Eur J Cancer; 1992; 28A(10):1670-6. PubMed ID: 1389483
[TBL] [Abstract][Full Text] [Related]
2. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
8. Pirarubicin in advanced breast cancer: a French cooperative phase II study.
Spielmann M; Kerbrat P; Delozier T; Fumoleau P; Monnier A; Chevallier B; Bastit P; Namer M; Cattan A; Lucas P
Eur J Cancer; 1990; 26(7):821-3. PubMed ID: 2145903
[TBL] [Abstract][Full Text] [Related]
9. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pirarubicin in metastatic breast cancer.
Kleeberg UR; Reichel L; Wander HE; Beyer JH; Essers U; Fiebig HH; Salewski E; Greifenberg B; Edler L
Onkologie; 1990 Jun; 13(3):175-9. PubMed ID: 2204003
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pirarubicin (THP-adriamycin) in metastatic breast cancer patients.
Lenk H; Tanneberger S; Wiener N; Giesske H; Gärtner S; Geyer J; Rotte KH
Oncology; 1990; 47(2):97-100. PubMed ID: 2314831
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
Delozier T; Vernhes JC
Bull Cancer; 1991 Nov; 78(11):1013-25. PubMed ID: 1369547
[TBL] [Abstract][Full Text] [Related]
14. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
Okada Y; Horikawa K; Sano M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
[TBL] [Abstract][Full Text] [Related]
15. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
Namer M; Soler-Michel P; Turpin F; Chinet-Charrot P; de Gislain C; Pouillart P; Delozier T; Luporsi E; Etienne PL; Schraub S; Eymard JC; Serin D; Ganem G; Calais G; Maillart P; Colin P; Trillet-Lenoir V; Prevost G; Tigaud D; Clavère P; Marti P; Romieu G; Wendling JL
Eur J Cancer; 2001 Jun; 37(9):1132-40. PubMed ID: 11378344
[TBL] [Abstract][Full Text] [Related]
16. [THP-adriamycin: status of the clinical development of a new anthracycline in France].
Herait P
Pathol Biol (Paris); 1990 Jan; 38(1):64-8. PubMed ID: 2308782
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
18. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
19. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
20. [Pirarubicin (THP-adriamycin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2819-27. PubMed ID: 3046496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
